stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) EPS (diluted)
Jazz Pharmaceuticals PLC's EPS (diluted) for fiscal 2025 was −$5.84, compared with $8.65 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.95. Over the past ten years it has ranged from −$5.84 (fiscal 2025) to $9.09 (fiscal 2019) — the current reading is the lowest in ten years. Jazz Pharmaceuticals PLC ranks 20th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$5.84 | — |
| FY2024 | $8.65 | 41.80% |
| FY2023 | $6.10 | — |
| FY2022 | −$3.58 | — |
| FY2021 | −$5.52 | — |
| FY2020 | $4.22 | (53.58%) |
| FY2019 | $9.09 | 24.52% |
| FY2018 | $7.30 | (8.29%) |
| FY2017 | $7.96 | 24.18% |
| FY2016 | $6.41 | 22.56% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$7.47 | — |
| Jun 2026 | $2.78 | (37.25%) |
| Mar 2026 | $4.43 | 38.01% |
| Dec 2025 | $3.21 | (21.32%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ASND Ascendis Pharma A/S compare | $12.89 |
| HALO Halozyme Therapeutics, Inc. compare | $3.93 |
| EXEL Exelixis, Inc. compare | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC | $2.95 |
| TECH Bio-Techne Corp compare | $1.15 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on JAZZ
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement